

**UNITED STATES BANKRUPTCY COURT
SOUTHERN DISTRICT OF NEW YORK**

In re:

PURDUE PHARMA L.P., *et al.*,

Debtors.¹

Chapter 11

Case No. 19-23649 (RDD)

(Jointly Administered)

**SEVENTEENTH MONTHLY FEE STATEMENT OF FTI CONSULTING, INC. FOR
COMPENSATION FOR SERVICES RENDERED AND REIMBURSEMENT OF
EXPENSES INCURRED AS FINANCIAL ADVISOR TO THE AD HOC COMMITTEE
OF GOVERNMENTAL AND OTHER CONTINGENT LITIGATION CLAIMANTS FOR
THE PERIOD FROM FEBRUARY 1, 2021 THROUGH FEBRUARY 28, 2021**

Name of Applicant:	FTI Consulting, Inc.
Authorized to provide Professional Services to:	Ad Hoc Committee of Governmental and Other Contingent Litigation Claimants
Date of Order Approving Debtors' Payment of Fees and Expenses of Applicant:	December 2, 2019 [ECF No. 553]
Period for which compensation and reimbursement is sought:	February 1, 2021 through February 28, 2021
Monthly Fees Incurred:	\$381,199.00

1. The Debtors in these chapter 11 cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifesciences Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717), and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

Monthly Expenses Incurred: \$9.99

Total Fees and Expenses Due: \$381,208.99

This is a: X monthly _____interim _____final application

PRIOR APPLICATIONS:

Docket No./Filed	Compensation Period	Requested		Approved	
		Fees	Expenses	Fees	Expenses
Docket No. 635 Filed On 12/9/2019	9/19/2019 – 10/31/2019	\$778,791.50	\$680.61	\$771,291.50	\$680.61
Docket No. 741 Filed On 1/13/2020	11/1/2019 – 11/30/2019	\$827,575.00	\$899.41	\$820,075.00	\$899.41
Docket No. 852 Filed on 2/20/2020	12/1/2019 – 12/31/2019	\$802,036.50	\$2,284.19	\$794,536.50	\$2,284.19
Docket No. 916 Filed on 3/12/2020	1/1/2020 – 1/31/2020	\$774,662.00	\$11,530.84	\$767,162.00	\$11,530.84
Docket No. 1090 Filed on 4/27/2020	2/1/2020 – 2/29/2020	\$615,089.00	\$6,141.22	\$610,714.00	\$6,141.22
Docket No. 1171 Filed on 5/19/2020	3/1/2020 – 3/31/2020	\$561,863.50	\$67.08	\$557,488.50	\$67.08
Docket No. 1251 Filed on 6/10/2020	4/1/2020 – 4/30/2020	\$428,303.00	\$1,732.28	\$423,928.00	\$1,732.28
Docket No. 1379 Filed on 7/13/2020	5/1/2020 – 5/31/2020	\$303,367.00	\$4,325.26	\$298,992.00	\$4,325.26
Docket No. 1651 Filed on 9/2/2020	6/1/2020 – 6/30/2020	\$374,753.00	\$96.90	\$372,253.00	\$ 96.90
Docket No. 1725 Filed on 9/25/2020	7/1/2020 – 7/31/2020	\$446,975.50	\$0.00	\$444,475.50	\$0.00
Docket No. 1850 Filed on 10/26/2020	8/1/2020 – 8/31/2020	\$261,092.00	\$108.25	\$258,592.00	\$108.25
Docket No. 1950 Filed on 10/26/2020	9/1/2020 – 9/30/2020	\$357,546.50	\$0.00	\$355,046.50	\$0.00
Docket No. 2031 Filed on 11/24/2020	9/19/2019 – 9/30/2020	\$44,462.00	\$0.00	\$41,462.60	\$0.00
Docket No. 2154 Filed on 12/18/2020	10/1/2020 – 10/31/2020	\$356,078.50	\$0.00	\$353,078.50	\$0.00
Docket No. 2308 Filed on 1/20/2021	11/1/2020 – 11/30/2020	\$450,827.00	\$0.00	\$447,827.60	\$0.00
Docket No. 2503 Filed on 3/17/2021	12/1/2020 – 12/31/2020	\$308,146.00	\$0.00	\$305,146.00	\$0.00
Docket No. 2504 Filed on 3/17/2021	1/1/2021 – 1/31/2021	\$493,773.50	\$0.00	\$490,773.50	\$0.00

Note: The fee examiner's agreed upon reductions of \$30,000, \$17,500, \$10,000, and \$15,000 were allocated evenly across fees from the first, second, third, and fourth interim period, respectively.

This statement (the “**Fee Statement**”) of FTI Consulting, Inc. (together with its wholly owned subsidiaries and independent contractors, “**FTI**”) as financial advisor to the Ad Hoc Committee of Governmental and Other Contingent Litigation Claimants of Purdue Pharma L.P., *et al.* (the “**Committee**”) is submitted in accordance with the *Order Establishing Procedures for Interim Compensation and Reimbursement of Expenses for Retained Professionals* [ECF No. 529] and the *Order Authorizing the Debtors to Assume the Reimbursement Agreement and Pay the Fees and Expenses of the Ad Hoc Committee’s Professionals* [ECF No. 553] entered on November 21, 2019 and December 2, 2019, respectively, (the “**Orders**”). In support of this Fee Statement, FTI respectfully states as follows.

1. The fees and expenses for the period from February 1, 2021 through and including February 28, 2021 (the “**Fee Period**”) amount to:

Professional Fees	\$381,199.00
Expenses	<u>9.99</u>
TOTAL	<u>\$381,208.99</u>

2. If no timely and proper objection is made by a party-in-interest within fourteen (14) days after service of this Fee Statement, the Debtors are authorized to pay 80% of professional fees and 100% of out-of-pocket expenses. These amounts are presented below.

Professional Fees at 80%	\$304,959.20
Expenses at 100%	<u>9.99</u>
TOTAL	<u>\$304,969.19</u>

3. The professionals providing services, hourly billing rates, the aggregate hours worked by each professional, and the aggregate hourly fees for each professional during the Fee Period are set forth on the schedule annexed hereto as **Exhibit “A.”**

4. A summary of aggregate hours worked and aggregate hourly fees for each task code during the Fee Period is set forth on the schedule annexed hereto as **Exhibit “B.”**
5. Detailed time entry by task code during the Fee Period is set forth on the schedule annexed hereto as **Exhibit “C.”**
6. A summary of expenses incurred during the Fifth Fee Period is set forth on the schedule annexed hereto as **Exhibit “D.”**
7. Detailed breakdown of the expenses incurred during the Fifth Fee Period is set forth on the schedule annexed hereto as **Exhibit “E.”**
8. FTI reserves the right to request, in subsequent fee statements and applications, reimbursement of any additional expenses incurred during the Fee Period, as such expenses may not have been captured to date in FTI’s billing system.

NOTICE AND OBJECTION PROCEDURES

9. Objections to this Fee Statement, if any, must be filed with the Court and served upon the Notice Parties so as to be received no later than May 26, 2021 (the “**Objection Deadline**”), setting forth the nature of the objection and the amount of fees or expenses at issue (an “**Objection**”).
10. If no objections to this Fee Statement are filed and served as set forth above, the Debtors shall promptly pay eighty percent (80%) of the fees and one hundred percent (100%) of the expenses identified herein.
11. If an objection to this Fee Statement is received on or before the Objection Deadline, the Debtors shall withhold payment of that portion of this Fee Statement to which the objection is directed and promptly pay the remainder of the fees and disbursements in the percentages set forth above. To the extent such an objection is not resolved, it shall be

preserved and scheduled for consideration at the next interim fee application hearing to be heard by the Court.

Dated: New York, New York
May 12, 2021

FTI CONSULTING, INC.
Financial Advisors to the Ad Hoc Committee of
Governmental and Other Contingent Litigation
Claimants of Purdue Pharma L.P.

By: /s/ Matthew Diaz
Matthew Diaz, Senior Managing Director
Three Times Square, 10th Floor
New York, New York 10036
Telephone: (212) 499-3611
Email: matt.diaz@fticonsulting.com

EXHIBIT A

**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
SUMMARY OF HOURS BY PROFESSIONAL
FOR THE PERIOD FEBRUARY 1, 2021 TO FEBRUARY 28, 2021**

Professional	Position	Specialty	Billing Rate	Total Hours	Total Fees
Diaz, Matthew	Sr Managing Director	Restructuring	\$ 1,120	83.2	\$ 93,184.00
Joffe, Steven	Sr Managing Director	Tax	1,165	17.7	20,620.50
Simms, Steven	Sr Managing Director	Restructuring	1,295	14.8	19,166.00
Bromberg, Brian	Director	Restructuring	840	182.3	153,132.00
Kim, Ye Darm	Sr Consultant	Restructuring	635	110.9	70,421.50
Kurtz, Emma	Consultant	Restructuring	470	52.5	24,675.00
GRAND TOTAL				461.4	\$ 381,199.00

EXHIBIT B

**PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649
SUMMARY OF HOURS BY TASK
FOR THE PERIOD FEBRUARY 1, 2021 TO FEBRUARY 28, 2021**

Task Code	Task Description	Total Hours	Total Fees
1	Current Operating Results & Events	6.6	\$ 3,102.00
3	Financing Matters (DIP, Exit, Other)	1.8	1,307.00
6	Asset Sales	38.7	30,508.50
7	Analysis of Domestic Business Plan	39.9	34,126.50
10	Analysis of Tax Issues	19.0	21,712.50
14	Analysis of Claims/Liab Subject to Compro	41.7	34,115.00
16	Analysis, Negotiate and Form of POR & DS	228.9	186,373.50
18	Review of Historical Transactions	45.3	36,213.00
19	Case Management	3.6	3,220.00
21	General Mtgs with Counsel and/or Ad Hoc Committee	18.3	17,050.00
22	Meetings with Other Parties	3.9	4,368.00
24	Preparation of Fee Application	13.5	9,009.00
28	Review of IAC Business Plan	0.2	94.00
GRAND TOTAL		461.4	\$ 381,199.00

EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

DETAIL OF TIME ENTRIES

FOR THE PERIOD FEBRUARY 1, 2021 TO FEBRUARY 28, 2021

Task Category	Date	Professional	Hours	Activity
1	2/1/2021	Kurtz, Emma	0.5	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	2/2/2021	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	2/3/2021	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	2/4/2021	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	2/5/2021	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	2/8/2021	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	2/9/2021	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	2/10/2021	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	2/11/2021	Kurtz, Emma	0.2	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	2/12/2021	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	2/15/2021	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	2/16/2021	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	2/17/2021	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	2/18/2021	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	2/19/2021	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	2/22/2021	Kurtz, Emma	0.4	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	2/23/2021	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	2/24/2021	Kurtz, Emma	0.2	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	2/25/2021	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1	2/26/2021	Kurtz, Emma	0.3	Prepare daily summary of dataroom updates, key docket filings and media coverage for distribution to the team.
1 Total			6.6	
3	2/1/2021	Bromberg, Brian	0.8	Discuss borrowing capacity with Debtors.
3	2/1/2021	Kim, Ye Darm	1.0	Participate in call with Debtors re: potential financing sources.
3 Total			1.8	
6	2/1/2021	Bromberg, Brian	1.3	Review potential buyer diligence responses.
6	2/2/2021	Kim, Ye Darm	0.2	Participate in call re: bid proposal opex sensitivity scenarios.
6	2/2/2021	Bromberg, Brian	0.5	Discuss buyer diligence with Houlihan.
6	2/2/2021	Kim, Ye Darm	0.5	Participate in call w/ UCC advisors re: bid diligence items.
6	2/2/2021	Diaz, Matthew	0.6	Participate in a call with the creditors' advisers to discuss the bid.
6	2/2/2021	Kim, Ye Darm	0.6	Participate on call w AHC professionals re: bid diligence request items.
6	2/2/2021	Bromberg, Brian	0.7	Discuss buyer diligence with UCC.
6	2/2/2021	Kim, Ye Darm	0.7	Update bid proposal license payment opex savings analysis.
6	2/2/2021	Bromberg, Brian	0.8	Discuss buyer diligence with Houlihan.
6	2/2/2021	Kim, Ye Darm	0.9	Participate in call re: bid diligence requests.

EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

DETAIL OF TIME ENTRIES

FOR THE PERIOD FEBRUARY 1, 2021 TO FEBRUARY 28, 2021

Task Category	Date	Professional	Hours	Activity
6	2/2/2021	Kim, Ye Darm	0.9	Participate in call with UCC advisors, HL, bidder re: bid structure alternatives.
6	2/2/2021	Diaz, Matthew	1.2	Participate in a call with a possible buyer.
6	2/2/2021	Bromberg, Brian	1.3	Discuss buyer counterproposal with buyer.
6	2/2/2021	Kim, Ye Darm	1.3	Prepare analysis re: bid proposal license payments with opex savings scenarios.
6	2/2/2021	Bromberg, Brian	1.9	Review buyer proposal calculations.
6	2/3/2021	Kim, Ye Darm	1.3	Call w/ bidder: bid structure alternatives.
6	2/4/2021	Bromberg, Brian	1.0	Discuss buyer proposal modeling.
6	2/8/2021	Diaz, Matthew	0.8	Participation in call with bidder re: diligence requests.
6	2/8/2021	Bromberg, Brian	1.9	Review latest buyer proposal terms.
6	2/8/2021	Bromberg, Brian	2.0	Participate in diligence call with buyer.
6	2/9/2021	Bromberg, Brian	0.5	Review latest buyer proposal terms.
6	2/9/2021	Kurtz, Emma	0.8	Participate in call with Houlihan and Kramer Levin re: bid and potential response.
6	2/9/2021	Bromberg, Brian	1.0	Participate in call with counsel and Houlihan re: buyer diligence.
6	2/11/2021	Kim, Ye Darm	0.7	Discuss ongoing workstreams re: bid diligence.
6	2/11/2021	Simms, Steven	0.7	Participate in call re: bid proposal.
6	2/11/2021	Kim, Ye Darm	0.7	Review latest HL presentation re: bid diligence.
6	2/11/2021	Kim, Ye Darm	0.8	Review HL one-pagers re: bid proposal diligence.
6	2/11/2021	Kim, Ye Darm	1.2	Review latest materials supporting updated bid proposal.
6	2/12/2021	Kim, Ye Darm	0.5	Participate in call re: ongoing bid diligence workstreams.
6	2/16/2021	Kim, Ye Darm	0.6	Review latest draft of bid proposal considerations presentation.
6	2/16/2021	Bromberg, Brian	0.7	Discuss buyer presentation with counsel ahead of call with NCSG.
6	2/16/2021	Simms, Steven	1.3	Participate in meeting with potential buyer.
6	2/16/2021	Bromberg, Brian	1.4	Participate in call with buyer and Committee.
6	2/16/2021	Kim, Ye Darm	1.7	Participate in call with AHC and bidder.
6	2/16/2021	Kim, Ye Darm	2.0	Participate in call with AHC and NCSG re: updated bid proposal.
6	2/16/2021	Bromberg, Brian	2.0	Participate in call with NCSG re: buyer.
6	2/18/2021	Kim, Ye Darm	0.7	Review bid GTN terms file.
6	2/19/2021	Kim, Ye Darm	1.0	Participate in call with bidder re: diligence questions list.
6 Total			38.7	
7	2/1/2021	Bromberg, Brian	0.5	Review materials for call with Debtors re: business plan forecasts.
7	2/1/2021	Bromberg, Brian	1.1	Participate in call with counsel on Debtor business plan scenarios.
7	2/1/2021	Bromberg, Brian	1.1	Participate in pre call on business plan forecasts.
7	2/1/2021	Bromberg, Brian	1.2	Participate in call with AGs on Debtors business plan scenarios.
7	2/1/2021	Bromberg, Brian	1.5	Review latest version of dist. values scenarios presentation.
7	2/2/2021	Bromberg, Brian	1.6	Review buyer proposal diligence questions.
7	2/9/2021	Bromberg, Brian	0.6	Participate in call with counsel and Houlihan re: upcoming diligence meetings.
7	2/9/2021	Diaz, Matthew	1.2	Review the business plan scenario slides for the AHC.
7	2/9/2021	Bromberg, Brian	1.5	Revise new core case slides re: business plan.
7	2/9/2021	Bromberg, Brian	1.6	Revise new slides re: business plan scenarios.
7	2/9/2021	Bromberg, Brian	2.0	Prepare new core case slides.
7	2/10/2021	Bromberg, Brian	0.9	Prepare target cash flow by segment summary.
7	2/10/2021	Bromberg, Brian	1.0	Participate in minimum cash discussion with Debtors.
7	2/11/2021	Kim, Ye Darm	0.3	Process revisions to downside impact slide.
7	2/11/2021	Bromberg, Brian	0.5	Participate in call with team re: domestic workplan.
7	2/11/2021	Bromberg, Brian	0.6	Discuss domestic business plan model with Houlihan.
7	2/11/2021	Bromberg, Brian	0.7	Revise waterfall portion of Houlihan model.
7	2/11/2021	Bromberg, Brian	0.9	Review domestic business plan model assumptions.
7	2/11/2021	Bromberg, Brian	1.5	Discuss and review core only deck revisions.
7	2/12/2021	Bromberg, Brian	0.7	Discuss minimum cash requirements with Debtors.
7	2/12/2021	Bromberg, Brian	0.7	Participate in discussion re: case update with internal team.
7	2/12/2021	Bromberg, Brian	2.0	Review latest domestic business plan model.
7	2/15/2021	Bromberg, Brian	0.9	Review updated core case business plan presentation.
7	2/15/2021	Bromberg, Brian	1.0	Discuss plan distributions model with Houlihan.
7	2/15/2021	Bromberg, Brian	1.2	Discuss plan distributions model with internal team.

EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

DETAIL OF TIME ENTRIES

FOR THE PERIOD FEBRUARY 1, 2021 TO FEBRUARY 28, 2021

Task Category	Date	Professional	Hours	Activity
7	2/15/2021	Bromberg, Brian	1.5	Finalize slides for updated core case business plan presentation.
7	2/16/2021	Bromberg, Brian	1.1	Discuss post emergence domestic business with MSGE.
7	2/17/2021	Bromberg, Brian	1.5	Finalize and send latest versions of domestic cash flow analysis.
7	2/19/2021	Bromberg, Brian	0.3	Review changes in domestic business plan.
7	2/19/2021	Bromberg, Brian	1.0	Participate in call on gross to net diligence.
7	2/22/2021	Bromberg, Brian	1.6	Review latest plan distributions model from HL.
7	2/23/2021	Bromberg, Brian	1.5	Participate in plan distributions option discussion w/ HL.
7	2/25/2021	Bromberg, Brian	0.9	Discuss plan distributions model and analysis with team.
7	2/25/2021	Diaz, Matthew	1.2	Review of the estimated sources and uses of cash at emergence.
7	2/26/2021	Bromberg, Brian	0.5	Summarize call re: plan distributions option for internal distribution.
7	2/26/2021	Bromberg, Brian	1.0	Discuss plan distributions option with clients.
7	2/27/2021	Bromberg, Brian	1.0	Review latest Xtampza actuals data.
7 Total			39.9	
10	2/1/2021	Joffe, Steven	1.8	Participate in call with AHC, NCSG, UCC re: tax structuring.
10	2/2/2021	Joffe, Steven	1.5	Participate in call with AHC re: tax considerations.
10	2/3/2021	Bromberg, Brian	0.7	Participate in tax call re: NewCo.
10	2/3/2021	Joffe, Steven	0.8	Participate in call with BR, KL re: tax structuring.
10	2/8/2021	Bromberg, Brian	0.6	Participate in call with tax team for update on IACs.
10	2/8/2021	Joffe, Steven	2.5	Review new bid proposal, Sackler contribution terms and call with BR and KL tax teams
10	2/10/2021	Joffe, Steven	0.4	Review IAC tax term sheets.
10	2/10/2021	Joffe, Steven	1.8	Participate in call with counsel re: tax issues.
10	2/16/2021	Joffe, Steven	0.5	Review of bid documents for potential tax issues.
10	2/16/2021	Joffe, Steven	1.5	Participate in meeting with bidder to discuss proposed deal and tax implications.
10	2/16/2021	Joffe, Steven	1.9	Participate in follow up call re: tax impact from bid.
10	2/17/2021	Joffe, Steven	1.0	Participate in call with AHC re: tax considerations for bid.
10	2/23/2021	Joffe, Steven	0.5	Review proposed changes to the IAC contribution agreement re: tax considerations.
10	2/24/2021	Joffe, Steven	1.1	Participate in AHC Call re: updates to tax impact.
10	2/25/2021	Joffe, Steven	1.1	Participate in call with counsel re: latest on tax analysis.
10	2/26/2021	Joffe, Steven	0.5	Review cash options re: tax considerations.
10	2/26/2021	Joffe, Steven	0.8	Participate in call regarding tax impact of plan distributions options.
10 Total			19.0	
14	2/3/2021	Kim, Ye Darm	0.4	Review Brattle presentation re: claims estimate.
14	2/3/2021	Bromberg, Brian	2.0	Review claims questions on plan term sheet.
14	2/4/2021	Bromberg, Brian	0.5	Review updated recovery analysis on claims.
14	2/4/2021	Bromberg, Brian	0.7	Discuss plan treatment of claims with Debtors.
14	2/4/2021	Bromberg, Brian	1.4	Review state claims presentation.
14	2/4/2021	Kim, Ye Darm	1.9	Prepare analysis re: DOJ claims sensitivities.
14	2/5/2021	Kim, Ye Darm	0.4	Process updates to the DOJ claim slides.
14	2/5/2021	Bromberg, Brian	0.6	Review response to counsel re: claims recoveries.
14	2/5/2021	Bromberg, Brian	0.6	Review updated recovery analysis slides on claims.
14	2/5/2021	Kim, Ye Darm	1.1	Produce updated slides re: illustrative DOJ claim.
14	2/5/2021	Diaz, Matthew	1.1	Review the sensitivity analysis in connection with the proposed payouts of the DOJ claims.
14	2/8/2021	Bromberg, Brian	0.9	Review the convenience class claim analysis.
14	2/8/2021	Bromberg, Brian	1.1	Process updates to the DOJ claim analysis slides.
14	2/8/2021	Diaz, Matthew	1.2	Review the plan claims and related proposed treatment.
14	2/8/2021	Diaz, Matthew	1.2	Review the updated DOJ claims analysis.
14	2/12/2021	Kim, Ye Darm	0.7	Review Debtors potential convenience class claims build up.
14	2/12/2021	Bromberg, Brian	0.9	Review updated convenience claim analysis.
14	2/12/2021	Kim, Ye Darm	1.4	Prepare draft analysis and slide re: illustrative convenience class.
14	2/13/2021	Bromberg, Brian	0.9	Review latest convenience claim analysis.
14	2/15/2021	Bromberg, Brian	0.7	Review latest convenience claim analysis.
14	2/15/2021	Kim, Ye Darm	1.2	Prepare analysis and slide on illustrative convenience class.

EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

DETAIL OF TIME ENTRIES

FOR THE PERIOD FEBRUARY 1, 2021 TO FEBRUARY 28, 2021

Task Category	Date	Professional	Hours	Activity
14	2/16/2021	Kim, Ye Darm	0.4	Process revisions to illustrative convenience class analysis slides.
14	2/16/2021	Kim, Ye Darm	0.7	Process revisions to illustrative convenience class analysis presentation.
14	2/16/2021	Diaz, Matthew	1.3	Review Purdue convenience class presentation and claim treatment slides.
14	2/17/2021	Diaz, Matthew	0.6	Review the updated DOJ claims analysis.
14	2/17/2021	Kim, Ye Darm	0.7	Process revisions to slides re: illustrative DOJ claim and convenience class.
14	2/17/2021	Bromberg, Brian	0.7	Review edited convenience class slide.
14	2/17/2021	Bromberg, Brian	0.7	Review the DOJ claims analysis.
14	2/17/2021	Bromberg, Brian	0.8	Prepare revisions to convenience class analysis.
14	2/17/2021	Kim, Ye Darm	1.2	Update analysis re: illustrative DOJ claim.
14	2/18/2021	Kim, Ye Darm	1.1	Prepare revisions to DOJ payout analysis.
14	2/22/2021	Kim, Ye Darm	0.3	Participate in call re: DOJ payout analysis.
14	2/22/2021	Diaz, Matthew	0.5	Review the updated DOJ claim analysis.
14	2/22/2021	Bromberg, Brian	0.7	Review the latest DOJ claim analysis.
14	2/22/2021	Kim, Ye Darm	0.9	Revise DOJ payout analysis for Sackler contribution assumption.
14	2/22/2021	Kim, Ye Darm	1.1	Process updates to slides re: DOJ payout.
14	2/22/2021	Bromberg, Brian	1.1	Revise updated DOJ claim slides.
14	2/22/2021	Kim, Ye Darm	1.3	Process revisions to DOJ payout analysis.
14	2/22/2021	Diaz, Matthew	2.7	Review claims classes and the plan treatment.
14	2/23/2021	Kim, Ye Darm	0.6	Process revisions to DOJ payout analysis.
14	2/23/2021	Bromberg, Brian	0.6	Review revised DOJ claims analysis.
14	2/23/2021	Kim, Ye Darm	0.8	Process revisions to DOJ analysis re: illustrative payouts.
14	2/23/2021	Bromberg, Brian	1.0	Participate in DOJ call re: claim.
14	2/23/2021	Bromberg, Brian	1.0	Review and provide revisions re: DOJ claims slides.
14 Total			41.7	
16	2/1/2021	Kim, Ye Darm	0.3	Process revisions to Sackler settlement sensitivity presentation.
16	2/1/2021	Diaz, Matthew	0.6	Participate in a call with the Debtors to discuss liquidity post emergence.
16	2/1/2021	Kim, Ye Darm	0.6	Review UCC presentation re: comparison of alternatives.
16	2/1/2021	Kim, Ye Darm	0.9	Update presentation re: Sackler settlement sensitivities for new scenarios.
16	2/1/2021	Kim, Ye Darm	1.6	Update analysis re: Sackler settlement for additional sensitivity scenarios.
16	2/1/2021	Diaz, Matthew	1.7	Participate in a call with the NCSG, MSGE and the AHC to discuss the distributable value analysis.
16	2/1/2021	Kim, Ye Darm	1.9	Participate in meeting with AHC/NCSG/MSGE group re: strategic options.
16	2/1/2021	Diaz, Matthew	1.9	Review the latest distributable value report.
16	2/1/2021	Simms, Steven	2.1	Participate in call with clients on plan proposal and strategic alternatives.
16	2/2/2021	Kim, Ye Darm	0.3	Process revisions to settlement contributions scenario summary.
16	2/2/2021	Kim, Ye Darm	0.5	Participate in call re: settlement contribution scenarios
16	2/2/2021	Kim, Ye Darm	0.6	Build crediting mechanism into settlement scenario model.
16	2/2/2021	Kim, Ye Darm	0.7	Review updated draft term sheet
16	2/2/2021	Simms, Steven	0.8	Participate in call re: plan issues.
16	2/2/2021	Kim, Ye Darm	1.5	Participate in call w AHC re: negotiations.
16	2/3/2021	Kim, Ye Darm	0.8	Review latest draft term sheet.
16	2/3/2021	Bromberg, Brian	1.3	Review operating parameters term sheet.
16	2/3/2021	Bromberg, Brian	1.5	Discuss operating parameters with team.
16	2/4/2021	Simms, Steven	0.8	Participate in call with Debtor on Plan term sheet.
16	2/4/2021	Bromberg, Brian	1.0	Discuss plan term sheet with Debtors.
16	2/4/2021	Kim, Ye Darm	1.0	Participate in call re: draft plan term sheet.
16	2/4/2021	Diaz, Matthew	1.2	Review and edit the plan term sheet demonstrative.
16	2/4/2021	Diaz, Matthew	1.3	Participate in a call with the Debtors to discuss the plan term sheet.
16	2/4/2021	Diaz, Matthew	1.8	Review the plan term sheet and related open items.
16	2/4/2021	Diaz, Matthew	1.9	Review of the distributable value analysis.
16	2/4/2021	Bromberg, Brian	2.3	Review and send comments on parameters term sheet.
16	2/5/2021	Kim, Ye Darm	0.9	Review latest distributable value scenario estimates.
16	2/5/2021	Kurtz, Emma	1.3	Analyze differences between IAC list included in Debtors' proposed contribution agreement with FTI IAC list to understand excluded entities.

EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

DETAIL OF TIME ENTRIES

FOR THE PERIOD FEBRUARY 1, 2021 TO FEBRUARY 28, 2021

Task Category	Date	Professional	Hours	Activity
16	2/5/2021	Diaz, Matthew	1.6	Review and develop responses to plan open item issues relating to claims and cash at emergence.
16	2/5/2021	Bromberg, Brian	2.7	Review contribution agreement and provide comments.
16	2/8/2021	Kurtz, Emma	0.4	Prepare further revisions to comparison of Sackler Contribution Agreement IAC list in Exhibit C to previously received lists of IAC entities.
16	2/8/2021	Simms, Steven	0.7	Review presentation on settlement options for AHC.
16	2/8/2021	Kurtz, Emma	0.9	Prepare revisions to analysis of proposed Sackler Contribution Agreement per internal comments.
16	2/8/2021	Bromberg, Brian	1.0	Continue to review contribution agreement and provide revisions.
16	2/8/2021	Diaz, Matthew	1.7	Review the updated distributable value analysis.
16	2/8/2021	Bromberg, Brian	2.2	Review contribution agreement and provide revisions.
16	2/9/2021	Kurtz, Emma	0.4	Prepare revisions to comparison analysis of Exhibit C of contribution agreement to IAC entity list per internal comments.
16	2/9/2021	Simms, Steven	0.5	Correspond with counsel on settlement items and presentation.
16	2/9/2021	Diaz, Matthew	0.5	Participate in a call with counsel to discuss the presentation to the Committee on various strategic alternatives.
16	2/9/2021	Bromberg, Brian	0.8	Write up summary of contribution agreement diligence.
16	2/9/2021	Bromberg, Brian	1.3	Review and comment on contribution agreement diligence.
16	2/9/2021	Bromberg, Brian	1.9	Review disclaimer plan distributions proposal.
16	2/9/2021	Kurtz, Emma	2.4	Prepare analysis of pledged entities in Exhibit D of the proposed contribution agreement to evaluate entities and assets not included.
16	2/10/2021	Kurtz, Emma	0.3	Attend internal call to discuss comparison of AHC term sheet proposal and the Debtors' response.
16	2/10/2021	Kurtz, Emma	0.4	Participate in follow-up call with AHC advisors to discuss Debtors' response to term sheet.
16	2/10/2021	Diaz, Matthew	0.5	Review the Debtors' counter to our financial plan provisions.
16	2/10/2021	Kurtz, Emma	0.6	Prepare revisions to draft slides comparing the AHC term sheet to the Debtors' response per internal comments.
16	2/10/2021	Diaz, Matthew	0.7	Review plan distributions opportunities analysis.
16	2/10/2021	Bromberg, Brian	0.8	Discuss operating parameters with team.
16	2/10/2021	Kurtz, Emma	0.8	Draft slides comparing the AHC term sheet and the Debtors' response re: distributions and operating parameters.
16	2/10/2021	Kurtz, Emma	1.1	Participate in call with the Debtors advisors to discuss the company's response to the AHC operating parameters and distributions term sheet.
16	2/10/2021	Diaz, Matthew	1.1	Review the updated slide deck to the committee on strategic alternatives and plan financial requirements.
16	2/10/2021	Bromberg, Brian	1.3	Finalize draft response on contribution agreement.
16	2/10/2021	Diaz, Matthew	1.5	Participate in a call with the Debtors' advisors and Houlihan to discuss the minimum cash distributions set forth in the plan.
16	2/10/2021	Kurtz, Emma	1.8	Prepare further revisions to analysis of Exhibit C and D of the contribution agreement to evaluate included IACs and pledged entities.
16	2/10/2021	Bromberg, Brian	1.8	Review prepared exhibits on contribution agreement.
16	2/10/2021	Diaz, Matthew	1.9	Participate in the AHC call to discuss the cash flow analysis, newco, Burke and other items.
16	2/10/2021	Bromberg, Brian	2.0	Work on operating parameters slides and model.
16	2/10/2021	Bromberg, Brian	3.4	Work on operating parameters slides and model.
16	2/11/2021	Kurtz, Emma	0.2	Prepare revisions to diligence request list re: Sackler contribution agreement per internal comments.
16	2/11/2021	Kurtz, Emma	0.3	Attend call with HL to discuss updates to minimum cash and revised scenarios.
16	2/11/2021	Kurtz, Emma	0.4	Participate on call with Counsel re: potential AHC response to Sackler Contribution Agreement.
16	2/11/2021	Kim, Ye Darm	0.4	Review analysis re: illustrative claims distributions.
16	2/11/2021	Kim, Ye Darm	0.4	Review UCC analysis re: comparison of Sackler contribution scenarios.
16	2/11/2021	Kim, Ye Darm	0.5	Participate in call w HL re: updated tax assumptions to cash flow.

EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

DETAIL OF TIME ENTRIES

FOR THE PERIOD FEBRUARY 1, 2021 TO FEBRUARY 28, 2021

Task Category	Date	Professional	Hours	Activity
16	2/11/2021	Bromberg, Brian	0.6	Discuss contribution agreement comments with counsel.
16	2/11/2021	Kurtz, Emma	0.7	Draft diligence questions list re: Sackler Contribution Agreement.
16	2/11/2021	Kim, Ye Darm	0.9	Update allocation analysis presentation slides.
16	2/11/2021	Bromberg, Brian	1.0	Review contribution agreement outstanding diligence list.
16	2/11/2021	Bromberg, Brian	1.0	Review latest draft of the plan distributions analysis.
16	2/11/2021	Bromberg, Brian	1.4	Review MDT proceeds and expenses analysis.
16	2/11/2021	Bromberg, Brian	1.8	Prepare new waterfall analysis with different contribution assumptions.
16	2/11/2021	Kim, Ye Darm	3.3	Update allocation model re: distributable value.
16	2/12/2021	Kurtz, Emma	0.3	Discuss internally re: analysis of Debtors' response to AHC term sheet and draft slides.
16	2/12/2021	Kurtz, Emma	0.3	Participate in call with PJT to discuss cash flow build to Debtors' proposed minimum distributions in plan term sheet.
16	2/12/2021	Kim, Ye Darm	0.5	Review HL slides on bid transaction considerations.
16	2/12/2021	Kim, Ye Darm	0.6	Participate in call re: minimum distribution workplan.
16	2/12/2021	Simms, Steven	0.6	Participate in correspondence re: Debtor Plan and strategic alternatives.
16	2/12/2021	Kim, Ye Darm	0.6	Review PJT draft slides on minimum distribution and operating parameters.
16	2/12/2021	Kim, Ye Darm	0.7	Participate in call with PJT re: minimum distribution considerations.
16	2/12/2021	Bromberg, Brian	0.7	Review Debtor counter on distributions.
16	2/12/2021	Kim, Ye Darm	0.8	Review HL one-pager analyses re: updated bid proposal.
16	2/12/2021	Kurtz, Emma	0.9	Draft slides comparing AHC term sheet proposal and Debtors' updated response re: operating parameters and distributions.
16	2/12/2021	Kim, Ye Darm	1.1	Review HL plan distributions draft scenario analysis.
16	2/12/2021	Kurtz, Emma	1.2	Prepare revisions to slides re: AHC term sheet and Debtors' response per internal comments.
16	2/12/2021	Bromberg, Brian	1.4	Review Debtors counterproposal presentation slides.
16	2/12/2021	Bromberg, Brian	1.8	Review Houlihan plan distributions model calculations.
16	2/12/2021	Bromberg, Brian	1.9	Process revisions to OpCo distribution analysis.
16	2/12/2021	Diaz, Matthew	2.0	Review the latest draft plan.
16	2/12/2021	Kim, Ye Darm	2.7	Prepare bridge analysis re: prior distributable value assumptions.
16	2/13/2021	Bromberg, Brian	0.5	Review latest revisions on contribution diligence items.
16	2/13/2021	Kurtz, Emma	0.8	Prepare further revisions to presentation re: AHC term sheet and Debtors' response per internal comments.
16	2/13/2021	Bromberg, Brian	1.1	Review updated Houlihan plan distributions model calculations.
16	2/13/2021	Bromberg, Brian	1.2	Discuss Debtors' operating parameters counterproposal slides with team.
16	2/13/2021	Bromberg, Brian	1.5	Review Debtors' operating parameters counterproposal slides.
16	2/13/2021	Diaz, Matthew	1.8	Review the updated plan distributions analysis.
16	2/13/2021	Bromberg, Brian	3.4	Review plan draft and provide commentary.
16	2/14/2021	Kurtz, Emma	0.3	Prepare revisions to analysis comparing the AHC's original term sheet proposal, revised term sheet proposal, and the Debtors' latest response.
16	2/14/2021	Kurtz, Emma	0.8	Review audited 2018 IAC financials to ensure the entities are included in Exhibit C of the Sackler Contribution Agreement.
16	2/14/2021	Kurtz, Emma	0.9	Prepare revisions to analysis of Sackler contribution agreement and follow-up diligence questions re: additional lists of IAC entities.
16	2/14/2021	Diaz, Matthew	1.8	Review the latest draft of the operating parameters presentation.
16	2/15/2021	Kim, Ye Darm	0.7	Review latest draft of HL scenarios presentation.
16	2/15/2021	Kurtz, Emma	0.9	Prepare revisions to operating parameters and disbursements slides re: response to Debtors' term sheet.
16	2/15/2021	Kim, Ye Darm	0.9	Update prior model to estimate distributable value impact from delayed emergence.
16	2/15/2021	Kurtz, Emma	1.0	Attend internal call to discuss HL disclaiming states analysis.
16	2/15/2021	Kim, Ye Darm	1.0	Participate in call re: min distribution requirements.
16	2/15/2021	Kim, Ye Darm	1.1	Analyze variances between OpCo cash flows.
16	2/15/2021	Bromberg, Brian	1.2	Review impact of Sackler contribution assumptions.
16	2/15/2021	Bromberg, Brian	1.2	Review updated operating parameter counter numbers.
16	2/15/2021	Diaz, Matthew	1.3	Perform detailed review of the plan distributions analysis.

EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

DETAIL OF TIME ENTRIES

FOR THE PERIOD FEBRUARY 1, 2021 TO FEBRUARY 28, 2021

Task Category	Date	Professional	Hours	Activity
16	2/15/2021	Kim, Ye Darm	1.8	Prepare updated allocation slides for new emergence assumption.
16	2/15/2021	Bromberg, Brian	1.9	Update operating parameters proposal.
16	2/15/2021	Kurtz, Emma	1.9	Update term sheet analysis re: AHC expected distributions to reflect latest HL model incorporating 12/31/21 emergence.
16	2/15/2021	Diaz, Matthew	2.1	Review the latest operating parameters presentation.
16	2/15/2021	Bromberg, Brian	2.2	Review revised Houlihan plan distributions model calculations.
16	2/15/2021	Bromberg, Brian	2.4	Review extended emergence impact model re: distributable value.
16	2/15/2021	Kim, Ye Darm	3.1	Process revisions to allocation model for new emergence assumptions.
16	2/15/2021	Bromberg, Brian	3.2	Review impact of extended emergence date to forecasted distributable value.
16	2/16/2021	Diaz, Matthew	0.3	Participate in a call with PJT to discuss the proposed operating parameters.
16	2/16/2021	Kurtz, Emma	0.4	Prepare updates to proposed AHC response to Debtors' term sheet per internal comments.
16	2/16/2021	Simms, Steven	0.5	Participate in meeting with NCSG re: settlement diligence updates.
16	2/16/2021	Bromberg, Brian	0.6	Process revisions to operating parameters term sheet.
16	2/16/2021	Kim, Ye Darm	0.6	Review latest HL draft of core case overview presentation.
16	2/16/2021	Kim, Ye Darm	0.7	Process updates to adjust Sackler contribution for distributable value analysis.
16	2/16/2021	Bromberg, Brian	0.9	Discuss operating parameters counters with team.
16	2/16/2021	Bromberg, Brian	0.9	Review slides on net distributable value.
16	2/16/2021	Bromberg, Brian	1.0	Draft summary of operating parameters offer.
16	2/16/2021	Bromberg, Brian	1.4	Review bridge analysis re: distributable value models.
16	2/16/2021	Diaz, Matthew	1.7	Review the Purdue operating parameters report.
16	2/16/2021	Kim, Ye Darm	2.2	Process revisions to bridge analysis between OpCo variances.
16	2/17/2021	Kurtz, Emma	0.3	Attend call with advisors re: diligence on trusts and questions for the Debtors to understand the contribution agreement.
16	2/17/2021	Kim, Ye Darm	0.7	Review the latest plan distributions analysis.
16	2/17/2021	Diaz, Matthew	1.1	Review the updated plan distributions analysis.
16	2/17/2021	Bromberg, Brian	1.2	Process updates to the operating parameters term sheet.
16	2/17/2021	Kim, Ye Darm	1.9	Participate in call re: plan issues/min cash requirements.
16	2/17/2021	Diaz, Matthew	2.0	Participate in a call with the AHC due diligence committee to discuss plan issues.
16	2/17/2021	Diaz, Matthew	2.1	Detail review of the operating parameters presentation.
16	2/17/2021	Bromberg, Brian	2.1	Participate in pre-call with subcommittee on plan issues.
16	2/18/2021	Simms, Steven	0.3	Review summary of settlement issues from counsel.
16	2/18/2021	Simms, Steven	0.6	Participate in correspondence on settlement items.
16	2/18/2021	Diaz, Matthew	0.6	Review the updated operating parameters proposal.
16	2/18/2021	Bromberg, Brian	1.5	Continue processing revisions to the operating parameters term sheet.
16	2/18/2021	Bromberg, Brian	1.5	Finalize and send operating parameters term sheet to Debtors advisors.
16	2/19/2021	Kurtz, Emma	0.3	Attend call with the Debtors' to discuss the AHC response to their latest term sheet proposal.
16	2/19/2021	Bromberg, Brian	0.6	Discuss operating parameters with Debtors.
16	2/19/2021	Kim, Ye Darm	0.6	Participate in call re: min disbursements.
16	2/19/2021	Kim, Ye Darm	0.7	Review draft governance term sheets.
16	2/19/2021	Bromberg, Brian	1.0	Discuss operating performance reporting with Debtors and summarize.
16	2/22/2021	Simms, Steven	0.4	Participate in correspondence on plan issues.
16	2/22/2021	Kim, Ye Darm	0.5	Review latest distributable value model from HL.
16	2/22/2021	Bromberg, Brian	1.4	Follow up with counsel on contribution agreement.
16	2/22/2021	Kim, Ye Darm	1.6	Review latest HL plan distributions analysis and model.
16	2/23/2021	Kurtz, Emma	0.3	Discuss internally re: case updates and deliverables related to plan negotiations and contribution agreement.
16	2/23/2021	Simms, Steven	0.4	Review summary report on outstanding plan issues.
16	2/23/2021	Kim, Ye Darm	0.5	Participate in call re: Plan obligation analysis.
16	2/23/2021	Bromberg, Brian	0.6	Discuss list of plan comments for counsel.
16	2/23/2021	Bromberg, Brian	0.7	Prepare DOJ presentation speaking points.
16	2/23/2021	Kim, Ye Darm	0.8	Participate in call re: PoR diligence workstreams.
16	2/23/2021	Kim, Ye Darm	0.8	Review latest HL plan distributions analysis slides and model.

EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

DETAIL OF TIME ENTRIES

FOR THE PERIOD FEBRUARY 1, 2021 TO FEBRUARY 28, 2021

Task Category	Date	Professional	Hours	Activity
16	2/23/2021	Kim, Ye Darm	1.0	Participate in call with the AHC/DOJ re: payouts.
16	2/23/2021	Diaz, Matthew	1.5	Participate in a call with the DOJ to discuss the plan process.
16	2/23/2021	Bromberg, Brian	1.7	Review the latest plan draft.
16	2/23/2021	Bromberg, Brian	1.8	Discuss workstreams re: plan of reorganization.
16	2/23/2021	Kim, Ye Darm	2.8	Prepare summary analysis of emergence obligations re: PoR.
16	2/23/2021	Diaz, Matthew	2.9	Perform detailed review and provide commentary on the proposed Purdue plan.
16	2/24/2021	Bromberg, Brian	1.2	Continue review of latest version of emergence cash sources and uses analysis.
16	2/24/2021	Bromberg, Brian	1.7	Review latest version of emergence cash sources and uses.
16	2/24/2021	Kim, Ye Darm	2.1	Process revisions to emergence obligation analysis re: PoR.
16	2/24/2021	Bromberg, Brian	3.0	Review and comment on emergence cash waterfall.
16	2/25/2021	Diaz, Matthew	0.5	Review the Debtors' term sheet counter.
16	2/25/2021	Bromberg, Brian	0.6	Request emergence date information from Debtors.
16	2/25/2021	Bromberg, Brian	0.7	Discuss minimum distributions with Debtors.
16	2/25/2021	Simms, Steven	0.7	Participate in correspondence on plan distributions and alternative plan options.
16	2/25/2021	Diaz, Matthew	0.8	Review the latest proposed plan distributions analysis.
16	2/25/2021	Bromberg, Brian	0.9	Revise and send cash flow table for operating parameters.
16	2/25/2021	Kurtz, Emma	1.0	Attend call with Debtors' advisors re: response to AHC proposed term sheet, including operating parameters and disbursements.
16	2/25/2021	Diaz, Matthew	1.0	Participate in a call with the Debtors' advisors to discuss their proposed operating parameters counter.
16	2/25/2021	Kim, Ye Darm	1.0	Participate in call re: min disbursement requirements.
16	2/25/2021	Kim, Ye Darm	1.1	Participate in meeting re: plan distributions and emergence cash.
16	2/25/2021	Bromberg, Brian	1.2	Discuss plan distributions option and operating parameters with counsel.
16	2/25/2021	Diaz, Matthew	1.2	Participate in a call with the AHC's professionals to discuss the plan distributions analysis.
16	2/25/2021	Kim, Ye Darm	1.4	Participate in call re: plan distributions analysis with counsel.
16	2/25/2021	Bromberg, Brian	1.5	Review cash flows for operating parameters.
16	2/25/2021	Kurtz, Emma	2.1	Prepare further revisions to summary analysis of proposed net assets to identify value of pledged assets in the contribution agreement.
16	2/26/2021	Kim, Ye Darm	0.5	Participate in call re: operating parameters counter.
16	2/26/2021	Bromberg, Brian	0.6	Discuss updated operating parameters counters with team.
16	2/26/2021	Kim, Ye Darm	0.6	Review PJT operating parameters counter term sheet.
16	2/26/2021	Kim, Ye Darm	0.8	Participate in call w/ HL re: latest plan distributions model.
16	2/26/2021	Diaz, Matthew	0.9	Participate in a call with the Debtors to discuss emergence cash.
16	2/26/2021	Kurtz, Emma	1.0	Attend call with the Debtors' advisors re: plan issues.
16	2/26/2021	Bromberg, Brian	1.0	Discuss emergence cash and plan issues with Debtors.
16	2/26/2021	Kim, Ye Darm	1.1	Participate in call with Alix re: plan issues
16	2/26/2021	Kurtz, Emma	2.6	Prepare draft analysis of potential AHC response to the Debtors' latest term sheet using latest cash flow numbers and illustrative assumptions.
16	2/28/2021	Bromberg, Brian	1.0	Follow up with counsel on plan issues.
16 Total			228.9	
18	2/1/2021	Bromberg, Brian	1.0	Review Sackler settlement overview slides.
18	2/1/2021	Diaz, Matthew	1.6	Review the updated Sackler contribution analysis.
18	2/2/2021	Bromberg, Brian	1.2	Review and revise discounting for Sackler contribution slides.
18	2/2/2021	Diaz, Matthew	1.2	Review the updated Sackler settlement analysis.
18	2/3/2021	Diaz, Matthew	1.1	Review the updated Sackler settlement/contribution analysis.
18	2/4/2021	Diaz, Matthew	0.6	Review the proposed Sackler contribution settlement.
18	2/5/2021	Kim, Ye Darm	0.9	Review draft contribution agreement documents.
18	2/5/2021	Kim, Ye Darm	1.7	Prepare summary of asset breakout by payor group (Side-B).
18	2/8/2021	Bromberg, Brian	1.4	Review Sackler IAC entities in contribution agreement.
18	2/9/2021	Bromberg, Brian	1.0	Review Sackler asset reports for valuation figures.
18	2/9/2021	Diaz, Matthew	1.4	Review and provide comments to the proposed Sackler contribution agreement.
18	2/9/2021	Diaz, Matthew	1.4	Review the proposed Sackler contribution agreement analysis.
18	2/10/2021	Diaz, Matthew	0.9	Review proposed revisions to the Sackler contribution agreement.

EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

DETAIL OF TIME ENTRIES

FOR THE PERIOD FEBRUARY 1, 2021 TO FEBRUARY 28, 2021

Task Category	Date	Professional	Hours	Activity
18	2/11/2021	Diaz, Matthew	1.1	Review the latest Sackler contribution agreement.
18	2/12/2021	Kim, Ye Darm	0.9	Review UCC trust asset analysis presentation and analysis.
18	2/12/2021	Kurtz, Emma	1.1	Review previously provided information on Side A individuals' and trusts' net asset values to identify asset value of potential paying parties in credit support framework of contribution agreement.
18	2/12/2021	Kurtz, Emma	1.6	Prepare analysis of credit support framework section of contribution agreement to identify the various paying parties and contribution amounts for Side A and Side B.
18	2/13/2021	Diaz, Matthew	1.1	Review the latest Sackler contribution analysis.
18	2/14/2021	Diaz, Matthew	1.9	Review the latest Sackler contribution agreement.
18	2/17/2021	Kim, Ye Darm	0.5	Participate in call re: diligence on trusts.
18	2/17/2021	Bromberg, Brian	0.6	Discuss Sackler diligence with advisors of Debtors and UCC.
18	2/17/2021	Bromberg, Brian	1.2	Review Sackler asset information.
18	2/17/2021	Kurtz, Emma	1.4	Prepare revisions to analysis of Sackler family assets to incorporate A-side non-ICSP trusts and individuals to ensure completeness of credit support framework paying parties.
18	2/19/2021	Diaz, Matthew	0.4	Participate in a call with PJT to discuss the proposed Sackler contribution settlement.
18	2/19/2021	Diaz, Matthew	0.4	Review the updated Sackler contribution settlement.
18	2/23/2021	Kim, Ye Darm	0.4	Review Alix Trust diligence tracker requests.
18	2/23/2021	Kurtz, Emma	1.1	Prepare analysis of B-side paying parties identified in the proposed Sackler Contribution Agreement to evaluate net asset value.
18	2/24/2021	Bromberg, Brian	1.4	Review latest Sackler asset reports.
18	2/24/2021	Bromberg, Brian	1.7	Comment on summary of Sackler assets by paying group.
18	2/24/2021	Kurtz, Emma	2.6	Prepare revisions to analysis of proposed paying parties in Sackler Contribution Agreement re: net asset value per internal comments.
18	2/24/2021	Kurtz, Emma	3.3	Prepare analysis of A-side estimated paying parties per the family groups identified in the proposed Sackler Contribution Agreement to evaluate net asset value.
18	2/25/2021	Kim, Ye Darm	0.5	Participate in call re: paying parties trust analysis.
18	2/25/2021	Kim, Ye Darm	0.5	Participate in call w/ Huron re: Sackler Asset Reports.
18	2/25/2021	Kurtz, Emma	0.6	Attend call with Huron to discuss updated net asset reports for the A-side and B-side.
18	2/25/2021	Bromberg, Brian	0.7	Discuss Sackler assets with Huron Consulting.
18	2/25/2021	Bromberg, Brian	0.9	Finalize Sackler asset summary.
18	2/25/2021	Kurtz, Emma	1.1	Continue to prepare revisions to analysis of proposed paying parties in Sackler Contribution Agreement re: net asset value per internal comments.
18	2/25/2021	Bromberg, Brian	1.2	Comment on summary of Sackler assets by paying group.
18	2/26/2021	Diaz, Matthew	0.3	Participate in a call with Providence to discuss the Sackler due diligence.
18	2/26/2021	Bromberg, Brian	0.5	Coordinate diligence call on trusts assets.
18	2/26/2021	Diaz, Matthew	0.9	Review the Sackler contribution analysis.

EXHIBIT C

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

DETAIL OF TIME ENTRIES

FOR THE PERIOD FEBRUARY 1, 2021 TO FEBRUARY 28, 2021

Task Category	Date	Professional	Hours	Activity
18 Total			45.3	
19	2/15/2021	Simms, Steven	0.6	Review items on settlement for AHC.
19	2/17/2021	Kurtz, Emma	0.7	Review recently uploaded dataroom documents to update dataroom index and share with team.
19	2/21/2021	Bromberg, Brian	1.0	Gather professional fee estimate for 2021 from advisors to send to Debtors.
19	2/24/2021	Bromberg, Brian	0.4	Analyze professional fee estimate for 2021 from advisors to send to Debtors.
19	2/25/2021	Bromberg, Brian	0.5	Participate in discussion re: Purdue diligence workplan with team.
19	2/26/2021	Simms, Steven	0.4	Participate in internal correspondence re: outstanding plan items.
19 Total			3.6	
21	2/2/2021	Diaz, Matthew	1.3	Participate in a call with the AHC to discuss the status of mediation and other topics.
21	2/2/2021	Bromberg, Brian	1.3	Participate in weekly Committee call re: distributable value scenarios.
21	2/10/2021	Simms, Steven	1.8	Participate in weekly AHC meeting and re: plan alternatives.
21	2/10/2021	Bromberg, Brian	1.8	Participate in weekly Committee call re: operating parameters.
21	2/16/2021	Diaz, Matthew	1.1	Participate in a call with counsel and the mediation sub committee to prepare for the call with the NCSG.
21	2/17/2021	Kim, Ye Darm	1.0	Participate in call w AHC re: distributable value.
21	2/17/2021	Diaz, Matthew	1.1	Participate in the AHC call to discuss the plan, Sackler settlement and other topics.
21	2/17/2021	Bromberg, Brian	1.1	Participate in weekly Committee call re: diligence updates.
21	2/17/2021	Kurtz, Emma	2.1	Attend call with AHC advisors re: Debtors' proposed term sheet issues and AHC potential response.
21	2/24/2021	Bromberg, Brian	1.2	Participate in weekly Committee call re: diligence updates.
21	2/24/2021	Kim, Ye Darm	1.4	Participate in call with AHC re: bid diligence.
21	2/24/2021	Diaz, Matthew	1.5	Participate in the AHC call to discuss the plan process, Sackler settlement and other topics.
21	2/24/2021	Simms, Steven	1.6	Participate in call with AHC on outstanding plan items and diligence status.
21 Total			18.3	
22	2/16/2021	Diaz, Matthew	0.8	Participate in a call with the MSGE to discuss the buyer's proposal and certain plan issues.
22	2/16/2021	Diaz, Matthew	1.4	Review the updated diligence presentation to the NCSG.
22	2/16/2021	Diaz, Matthew	1.7	Participate in a call with the AHC and the NCSG to discuss the potential buyer and other topics.
22 Total			3.9	
24	2/15/2021	Kim, Ye Darm	3.5	Prepare the December fee app.
24	2/19/2021	Kim, Ye Darm	3.2	Prepare January 2021 Fee App.
24	2/22/2021	Diaz, Matthew	0.9	Review the December bill.
24	2/23/2021	Kim, Ye Darm	0.3	Process revisions to December bill.
24	2/24/2021	Kim, Ye Darm	2.5	Continue to prepare the January bill.
24	2/24/2021	Kim, Ye Darm	3.1	Prepare the January bill.
24 Total			13.5	
28	2/1/2021	Kurtz, Emma	0.2	Discuss internally re: analysis of general ledgers and reconciliation to global P&L.
28 Total			0.2	
Grand Total			461.4	

EXHIBIT D

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

SUMMARY OF EXPENSES

FOR THE PERIOD FEBRUARY 1, 2021 TO FEBRUARY 28, 2021

Expense Type	Amount
Other	\$ 9.99
Grand Total	\$ 9.99

EXHIBIT E

PURDUE PHARMA L.P., ET AL. - CASE NO. 19-23649

EXPENSE DETAIL

FOR THE PERIOD FEBRUARY 1, 2021 TO FEBRUARY 28, 2021

Date	Professional	Expense Type	Expense Detail	Amount
2/13/2021	Diaz, Matthew	Other	Access to internet to respond to case emails while working on flight.	\$ 9.99
Working Meals Total				\$ 9.99
Grand Total				\$ 9.99